文献速递白血病

抑制翻译起始因子eIF4A可灭活HSF1并在急性髓系白血病中发挥抗白血病活性

Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
PubMed 文献 · Leukemia · 2021-06-14

该研究探讨eIF4A抑制在急性髓系白血病(AML)中的治疗潜力。原代AML细胞中eIF4A1转录水平最高,eIF4A抑制剂rohinitib(RHT)可灭活HSF1并对祖细胞和白血病起始细胞发挥体内外抗白血病作用,尤其对FLT3-ITD突变细胞。HSF1敲低或RHT与FLT3抑制剂联用均显示协同作用。

要点

  • 原代AML细胞eIF4A1转录水平高于其他癌种,支持其作为治疗靶点
  • RHT抑制eIF4A可灭活HSF1,并对AML祖细胞和白血病起始细胞有体内外抗白血病活性
  • RHT与FLT3抑制剂在原代FLT3突变AML细胞中高度协同,为联合靶向提供依据

核心结论

  • 抑制eIF4A可灭活HSF1并对AML(尤其FLT3-ITD突变)发挥抗白血病活性,与FLT3抑制剂联用具有协同作用,为共靶向eIF4A和FLT3治疗FLT3突变AML提供新 rationale。

研究设计与样本

  • 研究对比原代AML细胞与其他癌种的eIF4A1转录水平,并使用强效特异性eIF4A抑制剂rohinitib(RHT)进行体外和体内实验。
  • 通过遗传学敲低HSF1评估其对FLT3突变AML细胞对临床FLT3抑制剂敏感性的影响,并在原代FLT3突变AML细胞中测试RHT与FLT3抑制剂的联合效果。

主要发现

  • 原代AML细胞相比其他癌种表现出最高的eIF4A1转录水平。
  • RHT抑制eIF4A可灭活HSF1,并对祖细胞和白血病起始细胞发挥显著的体外和体内抗白血病作用,尤其在FLT3-ITD突变细胞中。
  • 遗传学敲低HSF1可使FLT3突变AML细胞对临床FLT3抑制剂敏感,该协同作用在同时携带ITD和酪氨酸激酶结构域突变的FLT3双突变细胞中依然存在。
  • RHT与FLT3抑制剂联合在原代FLT3突变AML细胞中表现出高度协同作用。

临床怎么用

  • 对于FLT3突变(尤其ITD)的AML,可考虑将eIF4A抑制剂(如RHT)与FLT3抑制剂联合作为潜在治疗策略。
  • HSF1活性状态可能作为eIF4A抑制敏感性的参考指标,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eukaryotic initiation factor 4A (eIF4A), the enzymatic core of the eIF4F complex essential for translation initiation, plays a key role in the oncogenic reprogramming of protein synthesis, and thus is a putative therapeutic target in cancer. As important component of its anticancer activity, inhibition of translation initiation can alleviate oncogenic activation of HSF1, a stress-inducible transcription factor that enables cancer cell growth and survival. Here, we show that primary acute myeloid leukemia (AML) cells exhibit the highest transcript levels of eIF4A1 compared to other cancer types. eIF4A inhibition by the potent and specific compound rohinitib (RHT) inactivated HSF1 in these cells, and exerted pronounced in vitro and in vivo anti-leukemia effects against progenitor and leukemia-initiating cells, especially those with FLT3-internal tandem duplication (ITD). In addition to its own anti-leukemic activity, genetic knockdown of HSF1 also sensitized FLT3-mutant AML cells to clinical FLT3 inhibitors, and this synergy was conserved in FLT3 double-mutant cells carrying both ITD and tyrosine kinase domain mutations. Consistently, the combination of RHT and FLT3 inhibitors was highly synergistic in primary FLT3-mutated AML cells. Our results provide a novel therapeutic rationale for co-targeting eIF4A and FLT3 to address the clinical challenge of treating FLT3-mutant AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Nishida Y, Zhao R, Heese LE, et al. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia. 2021. PMID: 34127794. doi:10.1038/s41375-021-01308-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。